Author:
Li Gaopeng,Choi Jae Eun,Kryczek Ilona,Sun Yilun,Liao Peng,Li Shasha,Wei Shuang,Grove Sara,Vatan Linda,Nelson Reagan,Schaefer Grace,Allen Steven G.,Sankar Kamya,Fecher Leslie A.,Mendiratta-Lala Mishal,Frankel Timothy L.,Qin Angel,Waninger Jessica J.,Tezel Alangoya,Alva Ajjai,Lao Christopher D.,Ramnath Nithya,Cieslik Marcin,Harms Paul W.,Green Michael D.,Chinnaiyan Arul M.,Zou Weiping
Reference88 articles.
1. Primary, adaptive, and acquired resistance to cancer immunotherapy;Sharma;Cell,2017
2. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm;Robert;Nat. Rev. Clin. Oncol.,2020
3. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015
4. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations;Zou;Sci. Transl. Med.,2016
5. Pseudoprogression and immune-related response in solid tumors;Chiou;J. Clin. Oncol.,2015